Qingkun G. Jiang

Jiangxi Provincial Key Laboratory Of Oral Diseases
Nanchang, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Global Trends and Research Hotspots of Ferroptosis in Osteoarthritis: A Bibliometric and Visualized Study (2012-2026).

Global Trends and Research Hotspots of Ferroptosis in Osteoarthritis: A Bibliometric and Visualized Study (2012-2026).

Journal: The Journal of craniofacial surgery

Published: May 11, 2026

Network pharmacology and experimental validation reveal the therapeutic effect and Chemosensitization mechanism of Brusatol against oral squamous cell carcinoma.

Network pharmacology and experimental validation reveal the therapeutic effect and Chemosensitization mechanism of Brusatol against oral squamous cell carcinoma.

Journal: Cellular signalling

Published: April 27, 2026

PEG-GE11-modified nanoplatform for co-delivery of cisplatin and plumbagin in targeted therapy of oral squamous cell carcinoma.

PEG-GE11-modified nanoplatform for co-delivery of cisplatin and plumbagin in targeted therapy of oral squamous cell carcinoma.

Journal: RSC advances

Published: April 01, 2026

AMZ2 facilitates oral squamous cell carcinoma progression via USP10-mediated deubiquitination of SF3B1 and regulation of MCL-1 alternative splicing.

AMZ2 facilitates oral squamous cell carcinoma progression via USP10-mediated deubiquitination of SF3B1 and regulation of MCL-1 alternative splicing.

Journal: Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery

Published: December 30, 2025

DNPEP promotes the growth, metastasis, and cisplatin resistance of tongue squamous cell carcinoma through RACK1/ERK signaling pathway.

DNPEP promotes the growth, metastasis, and cisplatin resistance of tongue squamous cell carcinoma through RACK1/ERK signaling pathway.

Journal: Translational cancer research

Published: December 06, 2025

RNF152-mediated, ubiquitin-dependent degradation of HSP27 activates the PI3K/AKT pathway, driving synovial inflammatory cascades in TMJOA.

RNF152-mediated, ubiquitin-dependent degradation of HSP27 activates the PI3K/AKT pathway, driving synovial inflammatory cascades in TMJOA.

Journal: Arthritis research & therapy

Published: September 28, 2025

Environmental tobacco smoke exposure and periodontitis in non-smokers: a systematic review and meta-analysis.

Environmental tobacco smoke exposure and periodontitis in non-smokers: a systematic review and meta-analysis.

Journal: BMC oral health

Published: September 06, 2025

Plumbagin remodels the tumor immune microenvironment to overcome cisplatin resistance in tongue squamous cell carcinoma via KLF2 activation and ZWINT/NF-κB inhibition.

Plumbagin remodels the tumor immune microenvironment to overcome cisplatin resistance in tongue squamous cell carcinoma via KLF2 activation and ZWINT/NF-κB inhibition.

Journal: International immunopharmacology

Published: June 20, 2025

Pan-cancer analysis identified DOK3 as a novel biomarker for predicting prognosis and immunotherapy effectiveness.

Pan-cancer analysis identified DOK3 as a novel biomarker for predicting prognosis and immunotherapy effectiveness.

Journal: Discover oncology

Published: June 18, 2025

Exosomal SNHG26 mediates immunosuppression by impairing NK cells in tongue cancer.

Exosomal SNHG26 mediates immunosuppression by impairing NK cells in tongue cancer.

Journal: NPJ precision oncology

Published: June 10, 2025

Network pharmacology analysis and biological validation of molecular targets regulated by glaucocalyxin a in periodontitis.

Network pharmacology analysis and biological validation of molecular targets regulated by glaucocalyxin a in periodontitis.

Journal: Biochemical and biophysical research communications

Published: June 05, 2025

Abnormally Activated MNX1 Promotes Tumor Growth and Osimertinib Resistance and Predicts Survival in EGFR-Mutant Lung Adenocarcinoma.

Abnormally Activated MNX1 Promotes Tumor Growth and Osimertinib Resistance and Predicts Survival in EGFR-Mutant Lung Adenocarcinoma.

Journal: Drug design, development and therapy

Published: May 14, 2025

Showing 1-12 of 36

Last Updated: 09/26/2026